Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802535 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2014.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dermatological conditions in the intensive care unit at a tertiary care hospital in Riyadh, Saudi Arabia.
Saudi Med J
August 2024
From the College of Medicine (Altammami, Alswayed, AlJasser, Alkhodair), King Saud bin Abdulaziz University for Health Sciences, from the Department of Dermatology (AlJasser, Alkhodair), King Abdullah International Medical Research Center, from the Division of Dermatology (AlJasser), Ministry of National Guard Health Affairs, and from the Division of Pediatric Dermatology (Alkhodair), Department of Pediatrics, King Abdullah Specialist Children's Hospital, Riyadh, Kingdom of Saudi Arabia.
Article Synopsis
- The study aimed to examine skin conditions in patients admitted to the ICU, analyzing both those who developed dermatological issues during their stay and those whose conditions necessitated ICU care.
- A total of 344 patients were reviewed, revealing 365 distinct dermatological conditions, with the most common issues being skin infections, inflammatory diseases, and drug reactions.
- Key findings highlighted morbilliform drug eruption, contact dermatitis, and vasculitis as the top dermatological disorders observed among ICU patients.
Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets.
J Clin Invest
July 2024
Department of Dermatology, Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- Delays in drug hypersensitivity reactions can lead to serious health issues, and the role of different T cell types in these reactions needs to be better understood.* -
- Research used advanced methods to compare skin-resident memory T cells (TRMs) and other T cell subsets in severe conditions like Stevens-Johnson syndrome (SJS) and drug reactions with eosinophilia (DRESS), versus milder conditions like morbilliform drug eruption (MDE).* -
- Results showed that TRMs play a significant role in skin-limited diseases, while SJS/TEN and DRESS involved more recruitment of cytotoxic CD8+ T cells, highlighting different immune responses and suggesting new directions for treatment and understanding of
Delayed Skin Testing for Systemic Medications: Helpful or Not?
J Allergy Clin Immunol Pract
September 2024
Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia. Electronic address:
Article Synopsis
- Cutaneous adverse drug reactions include delayed reactions like morbilliform drug eruptions, which can improve over time, and severe cutaneous adverse reactions (SCARs), which require lifelong avoidance due to their lasting immunity and serious health risks.
- SCARs are linked to multiple drug interactions and include conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis, contributing to high rates of morbidity and mortality.
- Current diagnostic tests for SCARs, including skin testing and HLA typing, lack 100% negative predictive value, leading to ongoing debates about the effectiveness of delayed skin testing in diagnosing these reactions.
Histopathologic and Clinical Characterization of Brentuximab Vedotin-associated Rash.
Am J Surg Pathol
September 2024
Departments of Pathology.
Rash is one of the commonly observed adverse events with brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate used to treat cutaneous T-cell lymphoma (CTCL). However, clinical and histopathologic characterization of BV-associated rash (BVAR) is limited. Distinguishing BVAR from a patient's underlying CTCL can be challenging and can lead to treatment interruptions or even premature drug discontinuation.
View Article and Find Full Text PDFRare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.
Arch Dermatol Res
May 2024
Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA, 02115, USA.
Glucagon-like-peptide-1 (GLP-1) agonists are an emerging class of medications used to manage type 2 diabetes mellitus (T2DM) and weight loss, with demonstrated efficacy in reducing hemoglobin A1c levels, body mass index, and adverse cardiovascular events. While previous studies have reviewed notable cutaneous adverse effects with other antidiabetic medications, little is known about GLP-1 agonist-induced cutaneous reactions. Nevertheless, rare but significant cutaneous adverse reactions have been reported, including but not limited to dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!